118 related articles for article (PubMed ID: 24526737)
1. Myeloid suppressors decrease melanoma survival by abating tumor-fighting T cells.
Kiessling R; Mao Y; Pico de Coaña Y
Clin Cancer Res; 2014 Mar; 20(6):1401-3. PubMed ID: 24526737
[TBL] [Abstract][Full Text] [Related]
2. [A malignus melanoma immunterápiájának lehetoségei].
Ladányi A
Magy Onkol; 2003; 47(1):113-7. PubMed ID: 12704464
[TBL] [Abstract][Full Text] [Related]
3. [Immunotherapeutic possibilities for treatment of malignant melanomas].
Kokoschka EM
Hautarzt; 1979 Dec; 30(12):656-61. PubMed ID: 317654
[TBL] [Abstract][Full Text] [Related]
4. Melanoma-induced immunosuppression and its neutralization.
Umansky V; Sevko A
Semin Cancer Biol; 2012 Aug; 22(4):319-26. PubMed ID: 22349515
[TBL] [Abstract][Full Text] [Related]
5. Amino acid metabolism related to immune tolerance by MDSCs.
Yang B; Wang X; Ren X
Int Rev Immunol; 2012 Jun; 31(3):177-83. PubMed ID: 22587019
[TBL] [Abstract][Full Text] [Related]
6. Melanoma-educated CD14+ cells acquire a myeloid-derived suppressor cell phenotype through COX-2-dependent mechanisms.
Mao Y; Poschke I; Wennerberg E; Pico de Coaña Y; Egyhazi Brage S; Schultz I; Hansson J; Masucci G; Lundqvist A; Kiessling R
Cancer Res; 2013 Jul; 73(13):3877-87. PubMed ID: 23633486
[TBL] [Abstract][Full Text] [Related]
7. Frequent occurrence of high affinity T cells against MELOE-1 makes this antigen an attractive target for melanoma immunotherapy.
Godet Y; Desfrançois J; Vignard V; Schadendorf D; Khammari A; Dreno B; Jotereau F; Labarrière N
Eur J Immunol; 2010 Jun; 40(6):1786-94. PubMed ID: 20217862
[TBL] [Abstract][Full Text] [Related]
8. Failure at the effector phase: immune barriers at the level of the melanoma tumor microenvironment.
Gajewski TF
Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5256-61. PubMed ID: 17875753
[TBL] [Abstract][Full Text] [Related]
9. Increased frequencies of CD11b(+) CD33(+) CD14(+) HLA-DR(low) myeloid-derived suppressor cells are an early event in melanoma patients.
Rudolph BM; Loquai C; Gerwe A; Bacher N; Steinbrink K; Grabbe S; Tuettenberg A
Exp Dermatol; 2014 Mar; 23(3):202-4. PubMed ID: 24495013
[TBL] [Abstract][Full Text] [Related]
10. Antigen specificity of immune suppression by myeloid-derived suppressor cells.
Solito S; Bronte V; Mandruzzato S
J Leukoc Biol; 2011 Jul; 90(1):31-6. PubMed ID: 21486906
[TBL] [Abstract][Full Text] [Related]
11. Possibilities of immunotherapy and gene therapy for malignant melanoma.
Crowley NJ; Seigler HF
Semin Surg Oncol; 1993; 9(3):273-8. PubMed ID: 8516616
[TBL] [Abstract][Full Text] [Related]
12. [Immunotherapy for melanoma: how can tolerance be overcome?].
Robert C
Ann Dermatol Venereol; 2001; 128(6-7):709-13. PubMed ID: 11460031
[No Abstract] [Full Text] [Related]
13. Metastatic melanoma and immunotherapy.
Herzberg B; Fisher DE
Clin Immunol; 2016 Nov; 172():105-110. PubMed ID: 27430520
[TBL] [Abstract][Full Text] [Related]
14. [Are immunological treatments beneficial for malignant melanoma of the skin?].
Vihinen P; Vuoristo MS; Hernberg M; Pyrhönen S
Duodecim; 2010; 126(14):1701-10. PubMed ID: 20804089
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy of melanoma.
Parmiani G; Castelli C; Rivoltini L; Casati C; Tully GA; Novellino L; Patuzzo A; Tosi D; Anichini A; Santinami M
Semin Cancer Biol; 2003 Dec; 13(6):391-400. PubMed ID: 15001157
[TBL] [Abstract][Full Text] [Related]
16. Human tumor-released microvesicles promote the differentiation of myeloid cells with transforming growth factor-beta-mediated suppressive activity on T lymphocytes.
Valenti R; Huber V; Filipazzi P; Pilla L; Sovena G; Villa A; Corbelli A; Fais S; Parmiani G; Rivoltini L
Cancer Res; 2006 Sep; 66(18):9290-8. PubMed ID: 16982774
[TBL] [Abstract][Full Text] [Related]
17. Antigen-specific versus antigen-nonspecific immunotherapeutic approaches for human melanoma: the need for integration for optimal efficacy?
Tietze JK; Sckisel GD; Hsiao HH; Murphy WJ
Int Rev Immunol; 2011; 30(5-6):238-93. PubMed ID: 22053969
[TBL] [Abstract][Full Text] [Related]
18. [Development in the immunotherapy of malignant melanoma].
Tritsch H
Hautarzt; 1976 Jan; 27(1):1-7. PubMed ID: 767300
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy for melanoma.
Komenaka I; Hoerig H; Kaufman HL
Clin Dermatol; 2004; 22(3):251-65. PubMed ID: 15262312
[TBL] [Abstract][Full Text] [Related]
20. Immunocytokines: a new approach to immunotherapy of melanoma.
Reisfeld RA; Becker JC; Gillies SD
Melanoma Res; 1997 Aug; 7 Suppl 2():S99-106. PubMed ID: 9578424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
